Hypereosinophilic Syndrome Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy. Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00044304 -
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
|
Phase 2 | |
| Completed |
NCT00171912 -
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
|
Phase 2 | |
| Completed |
NCT00097370 -
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
|
Phase 3 | |
| Terminated |
NCT00171860 -
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
|
Phase 2 | |
| Recruiting |
NCT02581514 -
Eosinophilia Diagnosis
|
N/A | |
| Completed |
NCT00787384 -
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
|
Phase 2 | |
| Recruiting |
NCT03801434 -
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
|
Phase 2 | |
| Completed |
NCT00255346 -
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
|
Phase 2 | |
| Completed |
NCT03306043 -
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
|
Phase 3 | |
| Recruiting |
NCT04018118 -
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
|
||
| Completed |
NCT02836496 -
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
|
Phase 3 | |
| Completed |
NCT00086658 -
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
|
Phase 3 | |
| Recruiting |
NCT00276926 -
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
|
Phase 2 | |
| Active, not recruiting |
NCT02101138 -
Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
|
Phase 2 | |
| Recruiting |
NCT00091871 -
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
|
||
| Completed |
NCT01713504 -
Identification of New Markers in the Hypereosinophilic Syndrome
|
N/A | |
| Completed |
NCT00017862 -
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
|
Phase 2 | |
| Completed |
NCT00038675 -
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
|
N/A | |
| Terminated |
NCT00230334 -
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
|
Phase 2 | |
| Recruiting |
NCT04191304 -
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
|
Phase 3 |